jm25 Posted March 3, 2014 Share Posted March 3, 2014 Biosyent searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them. The company minimizes deal competition by focusing on niche products with peak penetration of between $2-15 million which is below the radar of mid and large pharma companies. Biosyent builds its sales and marketing teams around a product. This approach maximizes profit and minimizes costs, as sales teams are put in place only when needed and expand only when the product’s sales can support the expansion. Biosyent has 4 approved products: one in growth phase (FeraMAX), two in launch phase (Cathejell + FeraMAX Powder) and another in pre-launch (women’s health product). The company defines growth phase as minimum 20% growth year over year in product sales. The pipeline has 2 products in regulatory phase that will be launched in Q4 2014 and management is confident it can source 3 more products for 2015 launch. We believe the company will have 9 products on the market by year end 2015. - Great business model (like Paladin Labs). Minimal to no capex, strong growth - Significant growth and margins - Strong balance sheet (no debt, cash on hand) - Strong Management team with large insider ownership - Take a look at the purchase price multiple for Paladin - and you can understand the upside in valuation (Capital IQ says 6x sales, 18x EBITDA) http://espacemc.com/en/investment-ideas/biosyent Investor Presentation: https://docs.google.com/viewer?a=v&pid=sites&srcid=ZGVmYXVsdGRvbWFpbnxiaW9zeWVudHxneDoxYjA3MzgzYzdjNDM5NWM5 Link to comment Share on other sites More sharing options...
snowball82 Posted March 8, 2014 Share Posted March 8, 2014 This is one of my largest position. I started to buy at +/- $ 1.50. It's a great company : Hight growth & net margin & return on equity.... As value investor, often we look deeply the balance sheet and we find great bargain. Here we have to look the earning power. Do you think they will continue to grow at 70 % for few years ? Link to comment Share on other sites More sharing options...
snowball82 Posted March 9, 2014 Share Posted March 9, 2014 The CEO says the growth will be 50 % ! Link to comment Share on other sites More sharing options...
jm25 Posted March 9, 2014 Author Share Posted March 9, 2014 This is one of my largest position. I started to buy at +/- $ 1.50. It's a great company : Hight growth & net margin & return on equity.... As value investor, often we look deeply the balance sheet and we find great bargain. Here we have to look the earning power. Do you think they will continue to grow at 70 % for few years ? Do you still like it at these prices? Great balance sheet and growth here. 70% growth is tough, but if they can get some new products into the pipeline... Link to comment Share on other sites More sharing options...
snowball82 Posted March 9, 2014 Share Posted March 9, 2014 Yes it is a long term hold for me. Do you know another company with 57 % return on equity without long term debt + that growth rate ? Link to comment Share on other sites More sharing options...
jm25 Posted March 10, 2014 Author Share Posted March 10, 2014 Yes it is a long term hold for me. Do you know another company with 57 % return on equity without long term debt + that growth rate ? My thoughts exactly. Link to comment Share on other sites More sharing options...
Yours Truly Posted March 10, 2014 Share Posted March 10, 2014 i still need to do research on this company and thanks for sharing your thesis jm! Have you guys looked at Knights Therapeutic? it's run by the ex-owner/operator of Paladin Labs which if I recall runs a similar business model Link to comment Share on other sites More sharing options...
snowball82 Posted March 10, 2014 Share Posted March 10, 2014 Gud don't have EPS for now. Biosyent should earn more than $ 0.20 EPS this year. If the growth continue to be more than 50 % for few years... What will be the stock price 5 years from now with 20-25 X P/E ? ! Link to comment Share on other sites More sharing options...
snowball82 Posted March 11, 2014 Share Posted March 11, 2014 No response ? :) BioSyent Named to the 2014 TSX Venture Top 50® Ranking-Only TSX Venture Company to Be Recognized as a Top Performer for the Past 3 Consecutive Years http://finance.yahoo.com/news/biosyent-named-2014-tsx-venture-130000878.html If the company continu to growth like last 5 years... this stock should be baggers again. Just my opinion. Link to comment Share on other sites More sharing options...
jm25 Posted March 11, 2014 Author Share Posted March 11, 2014 No response ? :) BioSyent Named to the 2014 TSX Venture Top 50® Ranking-Only TSX Venture Company to Be Recognized as a Top Performer for the Past 3 Consecutive Years http://finance.yahoo.com/news/biosyent-named-2014-tsx-venture-130000878.html If the company continu to growth like last 5 years... this stock should be baggers again. Just my opinion. I agree snowball! I just want to sit back and let some others chime in and hear some other opinions. Link to comment Share on other sites More sharing options...
jm25 Posted March 12, 2014 Author Share Posted March 12, 2014 http://online.wsj.com/article/PR-CO-20140312-906103.html - Full year 2013 Sales of $7,799,426 increased by 55% versus 2012 - Revenue has grown at a compound annual growth rate (CAGR) of 67% over the last three years - 2013 Basic EPS of $0.14; Fully Diluted EPS of $0.13 - The company ended 2013 with $4,405,910 in working capital of which cash was $4,381,137 - The company remains debt-free and has an unutilized operating line of credit Link to comment Share on other sites More sharing options...
snowball82 Posted April 6, 2014 Share Posted April 6, 2014 Is this company a good target if consolidation in specialty-pharma ? Pediapharm (other investment idea) could become -later- another target. Competitors have MOUNTAINS of money ready to invest. Link to comment Share on other sites More sharing options...
Liberty Posted April 6, 2014 Share Posted April 6, 2014 Is this company a good target if consolidation in specialty-pharma ? Eventually, possibly if things go well, but I doubt management would want to sell for a while, it wouldn't maximize value for them if they think the business model can really keep scaling (insiders own a bit over 43% of the shares). Link to comment Share on other sites More sharing options...
snowball82 Posted April 8, 2014 Share Posted April 8, 2014 I agree, hope they won't sell before 4-5 years ! So Therapeutic Knight could like a larger sales network. Link to comment Share on other sites More sharing options...
Liberty Posted May 16, 2014 Share Posted May 16, 2014 Q1 is out: https://docs.google.com/viewer?a=v&pid=sites&srcid=ZGVmYXVsdGRvbWFpbnxiaW9zeWVudHxneDo5ZGI3YmEwZDM4N2U4NzA Q1 2014 Sales of $2,448,101 increased by 59% versus Q1 2013 Q1 2014 Revenue has grown at a compound annual growth rate (CAGR) of 65% over the corresponding quarters of the last three years Q1 2014 Pharmaceutical Sales of $2,343,008 were up 79% versus Q1 2013 Eighteen consecutive quarters of continued pharmaceutical sales growth Repeat orders for FeraMAX® 150 international customer Net Income Before Tax of $687,672 increased by 43% in Q1 2014 versus Q1 2013 Q1 2014 Net Income After Tax of $511,421 increased by 49% versus Q1 2013 Q1 2014 Diluted EPS of $0.04 versus $0.02 in Q1 2013 Trailing twelve months (TTM) fully diluted EPS of $0.15 The company remains debt-free and has an unutilized operating line of credit with Royal Bank of Canada Selected as a TSX Venture 50 Top Performer for three consecutive years – 2012, 2013 and 2014 2 new Urgent Care products awaiting Health Canada marketing approval Pre-launch activity for a new Women’s Health product – launch planned for second quarter of 2014 Pre-launch activity for a new Gastrointestinal Health product – launch planned for fourth quarter of 2014 Link to comment Share on other sites More sharing options...
snowball82 Posted May 16, 2014 Share Posted May 16, 2014 I love to see products launch planned this year :) Q1 2014 Pharmaceutical Sales of $2,343,008 were up 79% versus Q1 2013 2 new Urgent Care products awaiting Health Canada marketing approval Pre-launch activity for a new Women’s Health product – launch planned for second quarter of 2014 Pre-launch activity for a new Gastrointestinal Health product – launch planned for fourth quarter of 2014 CEO presentation on the First Quarter at the following link http://www.biosyent.com/q1/#.U3aZB9J5PX8 Please if you have company name with better profitability/growth without debt let me know ! Link to comment Share on other sites More sharing options...
snowball82 Posted May 17, 2014 Share Posted May 17, 2014 My favorite part Future Product Pipeline "In August 2012 BioSyent Pharma Inc. signed an exclusive Licensing and Distribution Agreement with a European partner for two new products that will be marketed to Hospitals. These two urgent care drugs are supplied in a patented delivery system that offers technical advantages over existing alternatives and will be used in hospitals and acute care settings. The two new products were filed with Health Canada in Q2 2013. The Company will launch these products upon receiving approval. These products will provide hospitals, clinics, and healthcare professionals with improved patient safety as well as operational efficiencies and will complement BioSyent’s Hospital Division business. There are several additional products under development by our European partner and we look forward to exploring additional product candidates utilizing the same patented technology. Due diligence on the third product using this technology has commenced. The Company is also in discussion with several other potential partners for other new product opportunities. Link to comment Share on other sites More sharing options...
bz1516 Posted May 17, 2014 Share Posted May 17, 2014 Q2 likely to show even higher percentage eps growth yoy due to increase in the legacy eco friendly insecticide business, and the increase in sales from the new product launch this quarter. Much of the marketing costs are already in place for the product launch due to increase in number of employees already on board. H2 could be particularly strong. Link to comment Share on other sites More sharing options...
KCLarkin Posted May 17, 2014 Share Posted May 17, 2014 I've been watching this one for awhile but can't get comfortable with the price. Link to comment Share on other sites More sharing options...
gary17 Posted May 17, 2014 Share Posted May 17, 2014 KCLarkin I think it might be worth taking a look at how much owner's earnings this company can deliver over the next years.... what are the bear and bullish projections? Does anyone know what management does with the free cash flow? It appears that they generated $2M last year.... in cash.... do they use that to acquire new licenses? In other words, they have been very good at what they have been buying? Thanks Gary Link to comment Share on other sites More sharing options...
bz1516 Posted May 17, 2014 Share Posted May 17, 2014 I've been watching this one for awhile but can't get comfortable with the price. It's true the PE in absolute terms is high at ~25x, but the PEG is still very low with a growth rate of 50%. The PEG should be more important, especially when the growth rate has been so consistent. Link to comment Share on other sites More sharing options...
snowball82 Posted May 18, 2014 Share Posted May 18, 2014 Q1 is out: Repeat orders for FeraMAX® 150 international customer 2 new Urgent Care products awaiting Health Canada marketing approval Pre-launch activity for a new Women’s Health product – launch planned for second quarter of 2014 Pre-launch activity for a new Gastrointestinal Health product – launch planned for fourth quarter of 2014 Repeat orders for FeraMax 150 international customer is a very important event. Very hight net margin product growth, FIRST product for sale outside Canada, could be a catalyst for next level. Do we know who is the partner and which country is targeted ? Link to comment Share on other sites More sharing options...
KCLarkin Posted May 18, 2014 Share Posted May 18, 2014 I've been watching this one for awhile but can't get comfortable with the price. It's true the PE in absolute terms is high at ~25x, but the PEG is still very low with a growth rate of 50%. The PEG should be more important, especially when the growth rate has been so consistent. I like to swing at fat pitches. I also looked at PLB as a comparable. PLB was cheaper when it it had similar revenue and had a big fall shortly after. But in the long run, PLB was obviously a fantastic investment. IF RX follows PLB trajectory, it will pay off. I was very tempted when it fell towards $5 but I think it would have to drop back to $3.50 before I would take a sizeable position. Might still put some play money in. Good discussion of some of the risks here: http://boards.fool.com/donville-kent-31136737.aspx?sort=whole Link to comment Share on other sites More sharing options...
Liberty Posted May 21, 2014 Share Posted May 21, 2014 New product launched today: http://www.marketwired.com/press-release/biosyent-pharma-launches-new-repagyn-hormone-free-vaginal-suppositories-tsx-venture-rx-1912515.htm Link to comment Share on other sites More sharing options...
ArminvanBuyout Posted May 26, 2014 Share Posted May 26, 2014 Anyone know why the stock went up so much today? Not that I'm complaining 8) Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now